CMX Research
CMX Research Inc. is a privately held, Oakville-based niche Contract Research Organization founded in 1992 that provides full-service Phase I-IV clinical trial management, monitoring, regulatory affairs, and data services for global pharmaceutical, biotech, and medical device sponsors, with a specialty in urology and oncology.
- Company typePrivate
- Founded1992
- HeadquartersOakville, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CMX Research does
CMX Research Inc. is a privately held, niche Contract Research Organization headquartered in Oakville, Ontario, Canada. Founded in 1992 as a Site Management Organization, the company has evolved into a full-service CRO providing Phase I–IV clinical trial services for drug and medical device studies, with a stated specialty in urology and oncology. The business is founder-led by Dr. Richard Casey, MD, FRCS(C), an actively practicing urologist and principal investigator, whose clinical background positions CMX around protocol design quality and patient-friendly study execution rather than scale-driven volume.
The company's service portfolio is organized around four core offerings — Full Service CRO (project management, site monitoring, regulatory affairs, vendor procurement, medical writing, safety/medical monitoring, statistical analysis, protocol writing, and eDC data management), Investigator Network (clinical trial sites across Canada and the USA across community, hospital-based, and academic settings), Investigator-Led Trials support, and Monitoring Services (CRA-led SQV/SIV/IMV/COV visits) — supplemented by secondary services such as regulatory submissions to Health Canada and FDA, device trials, recruitment/advertising, and a newly added Pharmacovigilance module launched in 2024. Technology stack is conventional CRO tooling centred on electronic Data Capture (eDC) data management via third-party vendors; no proprietary AI/ML or platform-as-a-service components are disclosed.
CMX generates revenue on a professional-services, project-by-project basis through direct sales engagement with pharmaceutical organizations, biotech firms, and medical device manufacturers. Pricing is custom-tailored per study and not publicly disclosed. Target customers span large global pharma (Pfizer, Novartis, Roche, AstraZeneca, Bayer, Janssen, Lilly, Sanofi, BMS Canada, Amgen, AbbVie, among others), emerging biotech, device companies, and sub-contracted engagements with Tier-1 CROs (IQVIA, PPD, Icon, PRA Health Sciences, Syneos Health, Chiltern). Trials are executed across 13 countries, including Canada, the United States, and multiple European and Asian jurisdictions.
CMX Research firmographics
Firmographics- Name
- CMX Research
- Legal name
- CMX Research Inc.
- Website
- https://cmxres.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CMX Research Inc. is a privately held, Oakville-based niche Contract Research Organization founded in 1992 that provides full-service Phase I-IV clinical trial management, monitoring, regulatory affairs, and data services for global pharmaceutical, biotech, and medical device sponsors, with a specialty in urology and oncology.
- Ownership category
- akta.pro rank
CMX Research industry classification
Industry- Product category
- Contract Research Organization (CRO) / Clinical Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where CMX Research is headquartered
LocationHeadquarters
- HQ city
- Oakville
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
CMX Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: CMX Research generates revenue through providing full-service CRO services including clinical trial management, monitoring, regulatory affairs, data management, and pharmacovigilance services for Phase I-IV clinical trials. Revenue is earned through service contracts with pharmaceutical companies, biotech firms, and device manufacturers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
CMX Research product offering
Product offeringCore offering
CMX Research is a niche Contract Research Organization (CRO) that designs and executes Phase I-IV clinical trials for pharmaceutical, biotech, and medical device sponsors across urology, oncology, immunology, cardiology, dermatology, endocrinology, and respirology. The company delivers full-service clinical trial management including project management, site monitoring and training, regulatory affairs, vendor procurement, medical writing, safety and medical monitoring, statistical analysis, protocol writing, and eDC-based data management. Its services are anchored by the largest urology-oncology principal investigator network in Canada and the USA, and supplemented by recently launched Pharmacovigilance Services.
Product overview
CMX Research is a niche Contract Research Organization (CRO) that evolved from a Site Management Organization (SMO) founded in 1992. Its service portfolio is organized around four interconnected core offerings: Full Service CRO (spanning project management, site monitoring and training, regulatory affairs, vendor procurement, medical writing, safety/medical monitoring, statistical analysis, protocol writing and study design, and eDC data management), Investigator Network (providing access to clinical trial sites across Canada and the USA), Investigator-Led Trials (ILTs) support (covering study design through final report writing), and Monitoring Services (CRA-led visits from SQVs through COVs for Phase I–IV and BA/BE studies). These core services are supplemented by secondary offerings including protocol design, early-phase proof-of-concept studies, regulatory submissions to Health Canada and FDA, device trials, central advertising and recruitment, physician focus groups, and audits. A newly added Pharmacovigilance Services module rounds out the portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- Full Service CRO Comprehensive contract research organization services covering Phase I-IV clinical trials for pharmaceutical, biotech, and device sponsors, including project management, site monitoring, regulatory affairs, vendor procurement, medical writing, safety monitoring, statistical analysis, protocol writing, and eDC-based data management.
- Investigator Network Extensive network of clinical trial sites across Canada and the USA spanning community sites, hospital-based research organizations, and academic institutions, with a focus on urology and oncology principal investigators — described as the largest urology-oncology PI network in North America.
- Investigator-Led Trials (ILTs) Support services for investigator-initiated trials including study design and launch, study management, site selection and recruitment, budget-friendly pricing and grant support, strategic study support, data management and analysis, and final report writing.
- Monitoring Services Clinical trial monitoring conducted by trained and certified Clinical Research Associates (CRAs), including Site Qualification Visits (SQVs), Site Initiation Visits (SIVs), Interim Monitoring Visits (IMVs), and Close-Out Visits (COVs) for Phase I-IV and BA/BE studies.
- Secondary Services Additional services including protocol design and development, early phase / proof of concept studies, regulatory submissions to Health Canada and FDA, device trials, central advertising and recruitment services, call centre support, physician focus groups, and audits.
- Pharmacovigilance Services Newly launched pharmacovigilance services for safety and adverse event monitoring in clinical trials, extending CMX's service portfolio into post-trial and ongoing safety surveillance.
Quantifiable outcome
- Completed over 400 studies successfully since 1992
- +3 more outcomes
Companies that use CMX Research
Customer profileNamed customers33 records
Segments4 records
Ideal customer profiles3 records
CMX Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CMX Research partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered minor.
- AB ScienceminorPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- AbbVieminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- AmgenminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- AstraZenecaminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- BayerminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- Bristol Myers Squibb CanadaminorPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- JanssenminorPharmaceutical company (Johnson & Johnson subsidiary) listed as a client partner of CMX Research for clinical trial services.
- LillyminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- NovartisminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- PfizerminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- RocheminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- SanofiminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- Boehringer IngelheimminorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- Daiichi SankyominorGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- Ferring PharmaceuticalsminorPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
- ChilternminorCMX has worked with Chiltern as a CRO partner, providing clinical trial services.
- IQVIAminorCMX has collaborated with IQVIA as a CRO partner, providing clinical trial services.
- IconminorCMX has worked with Icon as a CRO partner, providing clinical trial services.
- PPDminorCMX has collaborated with PPD as a CRO partner, providing clinical trial services.
- PRA Health SciencesminorCMX has worked with PRA Health Sciences as a CRO partner, providing clinical trial services.
- Syneos HealthminorCMX has collaborated with Syneos Health as a CRO partner, providing clinical trial services.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
CMX Research competitors and assessment
Company assessmentEmerging players
- Theorem Clinical Research: Mid-size specialty CRO focused on oncology and complex therapeutics — comparable to CMX on therapeutic specialization and small/mid CRO scale, though with broader geographic footprint.
- Novum Pharmaceutical Research Services: Niche CRO with early-phase clinical pharmacology and BA/BE expertise — directly comparable to CMX's BA/BE monitoring line and Phase I capability, with similar size and specialty positioning.
Broad incumbents
- Quintiles (IQVIA): Largest global CRO and a documented CMX channel-partner/sub-contractor. Overlaps with CMX's full-service Phase I-IV offerings but operates at vastly greater scale across all therapeutic areas.
- Syneos Health / Fortrea: Large clinical and commercial services CRO (post-spin Fortrea) and a documented CMX channel partner — competes across Phase I-IV with broader scale and integrated commercialization.
- ICON plc: Top-3 global CRO (formed via PRA Health Sciences combination) and a documented CMX channel partner — competing broad CRO with full Phase I-IV capabilities that often sub-contracts site and monitoring work to specialists like CMX.
- PPD (Thermo Fisher Clinical Research): Top-5 global CRO within Thermo Fisher and a documented CMX channel partner — broad full-service CRO competing with CMX in oncology/urology sponsor work, often leveraging specialists for site execution.
Direct peers
- Premier Research: Specialty-focused CRO with therapeutic expertise in oncology, urology, rare disease and pediatrics — directly comparable on therapeutic specialization, mid-scale full-service delivery, and PI-relationship-driven model.
- Medpace: Mid-size, therapeutically-focused full-service CRO with a reputation for medical/scientific depth and investigator-driven execution — directly comparable to CMX's clinical-led, specialty-therapy model, but at substantially greater scale.
- Worldwide Clinical Trials: Mid-size specialty CRO with strong therapeutic-area depth in oncology, urology and CNS — competes head-to-head with CMX for specialty Phase II/III work and shares the same medical-led positioning.
- Clinipace Worldwide: Mid-size full-service CRO with oncology and specialty therapeutic expertise and a mix of sponsor and biotech clients — closely comparable on service breadth and therapeutic emphasis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
CMX Research social profiles
Digital presenceCMX Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
CMX Research leadership team
Management profileNumber of profiles
Profiles1 record
CMX Research funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CMX Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CMX Research
What does CMX Research do?
CMX Research is a niche Contract Research Organization (CRO) that designs and executes Phase I-IV clinical trials for pharmaceutical, biotech, and medical device sponsors across urology, oncology, immunology, cardiology, dermatology, endocrinology, and respirology. The company delivers full-service clinical trial management including project management, site monitoring and training, regulatory affairs, vendor procurement, medical writing, safety and medical monitoring, statistical analysis, protocol writing, and eDC-based data management. Its services are anchored by the largest urology-oncology principal investigator network in Canada and the USA, and supplemented by recently launched Pharmacovigilance Services.
Is CMX Research a public or private company?
CMX Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CMX Research founded?
CMX Research was founded in 1992. It employs 11 to 50 people.
Where is CMX Research based?
CMX Research is headquartered in Oakville, Canada, in the North America region.
How does CMX Research make money?
One revenue line is on record: clinical Research Services.
Who are CMX Research's main competitors?
Emerging players on record are Theorem Clinical Research and Novum Pharmaceutical Research Services. Broad incumbents are Quintiles (IQVIA), Syneos Health / Fortrea, ICON plc and PPD (Thermo Fisher Clinical Research). Direct peers are Premier Research, Medpace, Worldwide Clinical Trials and Clinipace Worldwide.
Does CMX Research have an API?
No public API is recorded for CMX Research.
What industry is CMX Research in?
CMX Research's product category is Contract Research Organization (CRO) / Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 54171 and its SIC code is 8731.